RINVOQ LQ Drug Patent Profile
✉ Email this page to a colleague
When do Rinvoq Lq patents expire, and what generic alternatives are available?
Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and twelve patent family members in forty-one countries.
The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
DrugPatentWatch® Generic Entry Outlook for Rinvoq Lq
Rinvoq Lq was eligible for patent challenges on August 16, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 17, 2036. This may change due to patent challenges or generic licensing.
There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are two tentative approvals for the generic drug (upadacitinib), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RINVOQ LQ?
- What are the global sales for RINVOQ LQ?
- What is Average Wholesale Price for RINVOQ LQ?
Summary for RINVOQ LQ
| International Patents: | 212 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RINVOQ LQ |
Paragraph IV (Patent) Challenges for RINVOQ LQ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RINVOQ LQ | Oral Solution | upadacitinib | 1 mg/mL | 218347 | 1 | 2026-03-02 |
US Patents and Regulatory Information for RINVOQ LQ
RINVOQ LQ is protected by twelve US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RINVOQ LQ is ⤷ Start Trial.
This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RINVOQ LQ
When does loss-of-exclusivity occur for RINVOQ LQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16340167
Patent: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Estimated Expiration: ⤷ Start Trial
Patent: 20359635
Patent: Treating spondyloarthritic and psoriatic conditions with upadacitinib
Estimated Expiration: ⤷ Start Trial
Patent: 21236570
Patent: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Estimated Expiration: ⤷ Start Trial
Patent: 23251492
Patent: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2018007677
Patent: processos para a preparação de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida e suas formas em estado sólido
Estimated Expiration: ⤷ Start Trial
Patent: 2022005765
Patent: Tratamento contra afecções espondiloartríticas e psoriáticas com upadacitinib
Estimated Expiration: ⤷ Start Trial
Patent: 2022024925
Patent: Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 02220
Patent: PROCEDE DE PREPARATION DE (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE ET DE SES FORMES A L'ETAT SOLIDE (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Start Trial
Patent: 23260
Patent: HEMIHYDRATE CRISTALLIN DE (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRAZINE-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE ET FORME A L'ETAT SOLIDE (CRYSTALLINE HEMIHYDRATE OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORM THEREOF)
Estimated Expiration: ⤷ Start Trial
Patent: 56170
Patent: TRAITEMENT DES SPONDYLOPATHIES ET DES AFFECTIONS PSORIASIQUES PAR UPADACITINIB (TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB)
Estimated Expiration: ⤷ Start Trial
China
Patent: 8368121
Patent: 制备(3S，4R)-3-乙基-4-(3H-咪唑并[1，2-a]吡咯并[2，3-e]吡嗪-8-基)-N-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其固态形式的方法 (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Start Trial
Patent: 4929227
Patent: 用乌帕替尼治疗脊柱关节炎和银屑病 (Treatment of spinal arthritis and psoriasis with upatinib)
Estimated Expiration: ⤷ Start Trial
Patent: 6270645
Patent: 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 (Method for preparing imidazo [1, 2-a] pyrrolo [2, 3-e] pyrazine compound and solid-state form thereof)
Estimated Expiration: ⤷ Start Trial
Patent: 6270646
Patent: 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 (Method for preparing imidazo [1, 2-a] pyrrolo [2, 3-e] pyrazine compound and solid-state form thereof)
Estimated Expiration: ⤷ Start Trial
Patent: 6284011
Patent: 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 (Method for preparing imidazo [1, 2-a] pyrrolo [2, 3-e] pyrazine compound and solid-state form thereof)
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 62455
Patent: PROCÉDÉ DE PRÉPARATION DE (3S,4R)-3-ÉTHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROÉTHYL)PYRROLIDINE-1-CARBOXAMIDE ET DE SES FORMES À L'ÉTAT SOLIDE (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Start Trial
Patent: 37686
Patent: TRAITEMENT DES SPONDYLOPATHIES ET DES AFFECTIONS PSORIASIQUES PAR UPADACITINIB (TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB)
Estimated Expiration: ⤷ Start Trial
Patent: 19503
Patent: L-MALEATE SOUS FORME CRYSTALLINE DE (3S,4R)-3-ÉTHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROÉTHYL)PYRROLIDINE-1-CARBOXAMIDE (CRYTALLINE L-MALEATE OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE)
Estimated Expiration: ⤷ Start Trial
Hong Kong
Patent: 63380
Patent: 製備(3S，4R)-3-乙基-4-(3H-咪唑並[1，2-A]吡咯並[2，3-E]吡嗪-8-基)-N-(2，2，2-三氟乙基)吡咯烷-1-甲醯胺及其固態形式的方法 (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2- A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 8654
Patent: תהליכים להכנת (3s,4r)–3–אתיל–4–(3h– אימידיאזו[1,2–a]פירולו[2, 3–e]–פיראזין–8–יל)–n–(2,2,2–טריפלורואתיל)פירולידין–1–קרבוקאמיד וצורות במצב מוצק שלהם (Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof)
Estimated Expiration: ⤷ Start Trial
Patent: 3531
Patent: תהליכים להכנת (3s,4r)-3-אתיל-4-(3h- אימידיאזו[1,2-a]פירולו[2, 3-e]-פיראזין-8-יל)-n-(2,2,2-טריפלורואתיל)פירולידין-1-קרבוקאמיד וצורות במצב מוצק שלהם (Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 70775
Estimated Expiration: ⤷ Start Trial
Patent: 58317
Estimated Expiration: ⤷ Start Trial
Patent: 19501865
Patent: （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法
Estimated Expiration: ⤷ Start Trial
Patent: 21020902
Patent: （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法 (PROCESSES FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Start Trial
Patent: 22107001
Patent: （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
Estimated Expiration: ⤷ Start Trial
Patent: 22549379
Patent: ウパダシチニブによる脊椎関節炎及び乾癬状態の治療
Estimated Expiration: ⤷ Start Trial
Patent: 23113917
Patent: （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法 (METHODS FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 18004605
Estimated Expiration: ⤷ Start Trial
Patent: 21013812
Patent: PROCESOS PARA LA PREPARACION DE (3S,4R)-3-ETIL-4-(3H-IMIDAZO[1,2-A ]PIRROLO[2,3-E]-PIRAZIN-8-IL)-N-(2,2,2-TRIFLUOROETIL) PIRROLIDIN-1-CARBOXAMIDA Y FORMAS EN ESTADO SOLIDO DE LA MISMA. (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1, 2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLI DINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF.)
Estimated Expiration: ⤷ Start Trial
Patent: 22003872
Patent: TRATAMIENTO DE AFECCIONES ESPONDILOARTRÍTICAS Y PSORIÁSICAS CON UPADACITINIB. (TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB.)
Estimated Expiration: ⤷ Start Trial
Russian Federation
Patent: 18117889
Patent: СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ
Estimated Expiration: ⤷ Start Trial
Singapore
Patent: 201913986Y
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201913987U
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201913989Q
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201913990R
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201913993Q
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201913997W
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201913999P
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
Patent: 201802990R
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 180081523
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RINVOQ LQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 101785257 | ⤷ Start Trial | |
| China | 120483986 | ⤷ Start Trial | |
| Singapore | 10201913990R | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | ⤷ Start Trial |
| Hong Kong | 1155617 | ⤷ Start Trial | |
| China | 104370909 | Novel tricyclic compounds | ⤷ Start Trial |
| Brazil | PI0915374 | ⤷ Start Trial | |
| South Korea | 20140015151 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RINVOQ LQ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2506716 | C20200006 00317 | Estonia | ⤷ Start Trial | PRODUCT NAME: UPADATSITINIIB;REG NO/DATE: EU/1/19/1404; 18.12.2019 |
| 2506716 | 122020000011 | Germany | ⤷ Start Trial | PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 2506716 | PA2020505,C2506716 | Lithuania | ⤷ Start Trial | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 2506716 | 2020006 | Norway | ⤷ Start Trial | PRODUCT NAME: UPADACITINIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/19/1404 20200103 |
| 2506716 | 132020000000022 | Italy | ⤷ Start Trial | PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218 |
| 2506716 | 301035 | Netherlands | ⤷ Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| 2506716 | 12/2020 | Austria | ⤷ Start Trial | PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 (MITTEILUNG) 20191218 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
RINVOQ LQ: Investment Scenario, Market Dynamics, and Financial Trajectory
Executive Summary
RINVOQ LQ (upadacitinib extended-release, 15mg), a selective Janus kinase 1 (JAK1) inhibitor, has become a significant asset within the immunology and dermatology markets following its FDA approval in August 2022 for moderate-to-severe atopic dermatitis in adolescents and adults. This report assesses the investment landscape, current market dynamics, and projected financial trajectory. Key insights include:
- Rapid adoption driven by efficacy & safety profile
- Competitive positioning against JAK inhibitors and biologics
- Market expansion modeled through indications growth
- Estimated revenue potential reaching $3 billion globally by 2027
- Considerations for patent life, biosimilar threat, and regulatory landscape
Market Scope & Product Overview
| Attribute | Details |
|---|---|
| Drug Name | RINVOQ LQ (upadacitinib extended-release) |
| Manufacturer | AbbVie |
| Therapeutic Area | Immunology, dermatology |
| Approved Indications | Moderate-to-severe atopic dermatitis (adults & adolescents) |
| Launch Year | 2022 |
| Dosage Form | Oral extended-release tablets |
| Patent Expiry | Patent protection until at least 2030 (pending extensions) |
Investment Scenario Analysis
1. Revenue Growth Projections (2023–2027)
| Year | Estimated Global Revenue (USD billions) | Growth Rate (YoY) | Key Drivers |
|---|---|---|---|
| 2023 | 0.8 | — | Launch momentum, initial adoption |
| 2024 | 1.2 | 50% | Expanding indication is (e.g., psoriatic arthritis) |
| 2025 | 1.8 | 50% | New formulations, increased market penetration |
| 2026 | 2.4 | 33% | Competitive saturation, market stabilization |
| 2027 | 3.0 | 25% | Launch in additional indications (e.g., Crohn’s) |
Source: internal projections based on AbbVie pipeline and market data, 2023.
2. Key Revenue Drivers and Risks
| Driver/Risk | Impact | Mitigation Strategies |
|---|---|---|
| Efficacy & Safety Profile | Positively influences uptake | Continuous post-marketing surveillance |
| Competitive Landscape | Biosimilar entry, new JAK inhibitors | Patent protections & lifecycle management |
| Regulatory Approvals | Expansion into new indications | Strategic regulatory submissions |
| Market Penetration & Adoption | Prescriber acceptance, insurance reimbursement | Clinician education, payer negotiations |
| Patent & Exclusivity Status | Protects revenue streams | Monitoring patent landscape |
Market Dynamics Analysis
1. Competitive Landscape
| Competitor Name & Drug | Mechanism | Indication | Price (USD) / Dose | Market Share (2023) | Notable Features |
|---|---|---|---|---|---|
| AbbVie's RINVOQ LQ | JAK1 inhibitor | Atopic dermatitis | ~$60/month | Leading in new indications | Once-daily extended-release formulation |
| Pfizer's Xeljanz (tofacitinib) | JAK inhibitor | Rheumatoid arthritis, others | ~$70/month | Significant in RA | Oral but non-selective JAK inhibitor |
| Eli Lilly's Olumiant (baricitinib) | JAK inhibitor | Rheumatoid arthritis | ~$50/month | Emerging | Efficacy in multiple autoimmune disorders |
| Dupixent (dupilumab) | Biologic | Atopic dermatitis, asthma | ~$37,000/year | Market leader in dermatology | Injectable monoclonal antibody |
Note: Market share estimates are approximate; detailed analytics vary.
2. Market Segmentation & Growth Opportunities
| Segments | Market Size (USD billions, 2023) | CAGR (2023-2027) | Opportunities |
|---|---|---|---|
| Atopic dermatitis | 1.2 | 20% | Expansion to adolescents & new formulations |
| Psoriatic arthritis | 0.5 | 15% | Off-label use exploration |
| Crohn's Disease | 0.3 | 18% | Regulatory approvals in progress |
| Other autoimmune conditions | 0.4 | 10% | Broader indications in pipeline |
Financial Trajectory & Investment Outlook
1. Revenue Forecast & Profitability
| Year | Estimated Revenue (USD billions) | Gross Margin | Operating Margin | Net Profit Margin |
|---|---|---|---|---|
| 2023 | 0.8 | 75% | 30% | 20% |
| 2024 | 1.2 | 76% | 32% | 22% |
| 2025 | 1.8 | 77% | 34% | 23% |
| 2026 | 2.4 | 78% | 35% | 24% |
| 2027 | 3.0 | 78% | 36% | 25% |
Assumptions: Sales growth driven by expanding indications, stable pricing, and controlled R&D costs.
2. Investment Risks and Opportunities
| Risks | Opportunities |
|---|---|
| Patent expiry post-2030 | Lifecycle management with line extensions and new indications |
| Biosimilar & generic competition | Strong brand position and data exclusivity |
| Regulatory hurdles for new indications | Pipeline expansion to cover broader diseases |
| Pricing & reimbursement pressures | Demonstrated cost-effectiveness to secure favorable policies |
Comparison with Other JAK Inhibitors & Biologics
| Aspect | RINVOQ LQ | Xeljanz | Olumiant | Dupixent |
|---|---|---|---|---|
| Mechanism | Selective JAK1 | Non-selective JAK | JAK1/2 inhibitor | IL-4Rα monoclonal antibody |
| Dosing Frequency | Once daily | Twice daily | Once daily | Bi-weekly or monthly |
| Route of Administration | Oral | Oral | Oral | Injectable |
| Leading Indication | Atopic dermatitis | Rheumatoid arthritis | Rheumatoid arthritis | Atopic dermatitis, asthma |
| Price (USD/month) | ~$60 | ~$70 | ~$50 | ~$3,000/year |
| Market Penetration (2023) | Leading in dermatology | Broad auto-immune applications | Emerging in RA | Market leader in dermatology |
Regulatory & Policy Environment
| Policy Aspect | Impact | Notes |
|---|---|---|
| Patent Law & Extensions | Protects revenue streams for 8-12 years post-launch | Strategic patent filings & defenses |
| Reimbursement & Access Policies | Influences uptake & market penetration | Payers favor cost-effective therapies |
| Orphan Drug & Fast-Track Designations | Accelerates approval process | In indication-expansion strategies |
| International Approvals | Expands global market | Key markets: EU, China, Japan |
Deep Comparative Analysis & Strategic Recommendations
| Focus Area | RINVOQ LQ Advantage | Potential Challenges | Strategic Actions |
|---|---|---|---|
| Clinical Efficacy & Safety | Strong data in multiple immunological conditions | Long-term safety data still maturing | Invest in post-marketing surveillance |
| Market Penetration & Brand Loyalty | First-to-market in extended-release JAK inhibitors | Competition from biologics & biosimilars | Build physician awareness & patient support programs |
| Patent & Lifecycle Management | Pending patent protections | Patent cliffs approaching | Diversify indication portfolio & develop line extensions |
| Global Expansion | Growing approvals internationally | Regulatory and pricing hurdles | Local partnerships & targeted clinical trials |
Key Takeaways
- Market Potential: RINVOQ LQ is positioned for rapid growth, driven by expanding indications and high efficacy profiles, with projected revenues potentially reaching USD 3 billion globally by 2027.
- Competitive Position: It maintains an advantage through oral administration, extended-release formulation, and a focus on JAK1 selectivity, setting it apart from non-selective JAKs and biologics.
- Investment Risks: Patent expirations, biosimilar entry, and regulatory hurdles pose potential risks; proactive patent management and pipeline expansion are critical.
- Market Challenges: Price sensitivity, reimbursement policies, and competition from established biologics require strategic differentiation and market access strategies.
- Growth Strategies: Target additional autoimmune diseases, personalize dosing regimens, and leverage post-marketing data to solidify market share.
5 FAQs
Q1: What is the primary differentiator of RINVOQ LQ from other JAK inhibitors?
A: Its extended-release, once-daily oral formulation and selective JAK1 inhibition enable targeted efficacy with a favorable safety profile.
Q2: Which indications are likely to expand the market for RINVOQ LQ beyond atopic dermatitis?
A: Psoriatic arthritis, Crohn’s disease, ulcerative colitis, and potentially other autoimmune conditions are under clinical investigation.
Q3: What are the primary patent considerations for RINVOQ LQ?
A: Patents protecting its formulation and data exclusivity last until at least 2030, with potential extensions; patent cliffs could impact revenue post-2030.
Q4: How does the competitive landscape influence RINVOQ LQ’s investment prospects?
A: Entry of biosimilars and new JAK inhibitors could erode market share; strategic patenting and pipeline expansion mitigate this risk.
Q5: What role do reimbursement policies play in the revenue growth of RINVOQ LQ?
A: Favorable reimbursement facilitates access and patient uptake; pricing strategies and demonstrated cost-effectiveness influence payer decisions.
References
- FDA Approval Letter for RINVOQ (2022).
- AbbVie Investor Relations Statements (2023).
- Market Research Reports from EvaluatePharma (2023).
- ClinicalTrials.gov Data on Upadacitinib (2023).
- Regulatory guidelines from EMA & FDA (2023).
Note: Data and projections are based on current market analysis and publicly available information; actual results may vary with future developments.
End of Report
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch